A global phase 2 trial
for children with achondroplasia (ACH)
The ACcomplisH Trial is a global phase 2 clinical trial evaluating the safety and efficacy of TransCon™ CNP, an investigational treatment for children with achondroplasia (ACH) designed to provide continuous exposure to C-type natriuretic peptide (CNP) with once-weekly administration. For a list of participating countries and sites, please see ClinicalTrials.gov.
Pre-pubertal children 2 to 10 years of age with ACH are invited to screen for trial eligibility.
After enrollment into the trial, participants will be randomly assigned to receive TransCon CNP or placebo in a 3:1 ratio. This means for every 4 participants, 3 will be randomly assigned to receive TransCon CNP and 1 will receive placebo. The randomization process to determine which medicine participants will receive is done via a computer system.
Both study medicines are given with a small needle that is inserted under the skin. Participants who successfully complete the ACcomplisH Trial may have the opportunity to receive TransCon CNP in a long-term safety trial.